Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions

Last updated: December 16, 2013
Sponsor: AGUNCO Obstetrics and Gynecology Centre
Overall Status: Completed

Phase

4

Condition

Pregnancy

Treatment

N/A

Clinical Study ID

NCT02016495
Mg-ALA
  • Ages 23-41
  • Female

Study Summary

To evaluate whether a combined supplementation of magnesium and lipoic acid is able to significantly reduce the incidence of uterine contractions and related episodes of hospitalization in pregnant women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 14-34 weeks of gestation

Exclusion

Exclusion Criteria:

  • Preexisting diabetes mellitus

  • Systolic blood pressure >140mm Hg

  • Cancer

  • lupus

  • hepatitis

  • HIV/AIDS

  • Diagnosed alcohol or chemical dependency

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Primary prevention of preterm labor is based on the early identification of risk factors and on appropriate treatments. Although several drugs are currently used, the identification of effective and safe agents able to improve both maternal and fetal health is still warranted.

In this study the efficacy a formulation based on magnesium and alpha-lipoic acid has been compared with placebo to evaluate the incidence of reduction of preterm delivery.

Three hundred pregnant women at 14-34 weeks of gestation were enrolled and randomly divided to receive a daily single tablet containing magnesium and alpha-lipoic acid supplement or placebo until delivery.

Connect with a study center

  • Clinica Villa delle Querce

    Naples,
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.